Abstract
Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Current Pharmaceutical Design
Title: The Platelet ATP and ADP Receptors
Volume: 12 Issue: 7
Author(s): C. Oury, E. Toth-Zsamboki, J. Vermylen and M. F. Hoylaerts
Affiliation:
Keywords: Hemostasis, thrombosis, adenine nucleotides, P2Y1, P2Y12, P2X1, antithrombotic therapy
Abstract: Adenine nucleotides, ADP and ATP, are coreleased from dense granules during platelet activation, as well as from endothelial cells and damaged red blood cells following vascular injury. Through autocrine and paracrine mechanisms, these extracellular signaling molecules interact with the platelet P2 receptors to amplify ongoing platelet activation. Two receptors for ADP, the Gq-protein-coupled P2Y1 and Gi-protein-coupled P2Y12 and one receptor for ATP, the P2X1 ion channel, have been identified on platelets. Due to distinct pharmacological properties and differential regulation, the P2Y and P2X receptors essentially operate on different scales of time and distance and trigger selective intracellular signaling cascades. Recent advances in the understanding of the P2Y receptor physiology have reinforced the concept of these receptors as useful targets for antithrombotic therapy. The function of P2X1 in platelet activation only recently started to be unraveled. This review focuses on recent findings on the physiology of these platelet ADP and ATP receptors, their distinct downstream intracellular signaling pathways as well as on the available agonists, antagonists and inhibitors that allow their pharmacological discrimination.
Export Options
About this article
Cite this article as:
Oury C., Toth-Zsamboki E., Vermylen J. and Hoylaerts F. M., The Platelet ATP and ADP Receptors, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056029
DOI https://dx.doi.org/10.2174/138161206776056029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apoptosis in Atherosclerosis: Virtue or Vice
Current Cardiology Reviews Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Calcific Aortic Valve Disease and Hypertension
Current Hypertension Reviews Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
Current Pharmaceutical Design Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology Effects of Pulmonary Blood Flow on Respiratory Mechanics: Measurements by the End-Inflation Occlusion Method in Healthy Rats After Acute Blood Volume Expansion
Current Respiratory Medicine Reviews Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Olive Oil-related Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality?
Current Pharmaceutical Design Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1
Current Hypertension Reviews Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers
Current Drug Safety The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design